Adapting to Change: Strategies for Pharma Service Providers, CROs, and R&D Partnerships in the Era of the Inflation Reduction Act

Register for this new webinar presented by the experts at Avalere Health, part of Fishawack Health.

Alongside other market forces and the recent pandemic, drug price negotiation and Part D redesign as established by the Inflation Reduction Act (IRA) will affect how pharmaceutical manufacturers and their partners pursue drug development in the coming years. All channel participants should understand the implications of these changes to make important strategic investments and operational preparations. 

During this webinar, panelists will discuss the type of changes that may be expected and discuss ways in which pharmaceutical stakeholders might approach near- and medium-term strategic planning, from go/no-go decisions through to product launch.  

Topics will include: 

  • Core IRA provisions and implementation timelines
  • Pharmaceutical research and development budgets, truncated ROI with IRA early product development and pipeline decision-making dynamics 

  • Valuable roles for contract research organizations (CROs), contract manufacturing organizations, and pharma services partners 

  • Evolution of decentralized trials: the role of digitalizing patient consent, patient monitoring, electronic patient-reported outcomes, and patient perspectives 

  • The influence of the IRA on real-world data utilization for optimal evidence generation and value-based pricing

FREE Ebook

Navigating the US payer landscape

Latest insights

Driving BioPharma Access in Europe: Insights for ...

PRMA Consulting becomes Avalere Health, creating the ...

World Orphan Drug Congress 2023: solutions for market ...